News ImmuneRegen NewsIR BioSciences Holdings, Inc. to Collaborate with Leading Clinical Services Company to Evaluate Radilex(TM) in Low-Level Radiation ExposureSCOTTSDALE, Ariz., Feb. 26 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO) announced today that it has entered into an agreement with The Translational Genomics Research Institute (TGen), a non- profit organization focused on developing earlier diagnostics and smarter treatments. The parties will collaborate to identify and develop innovative solutions to mitigate the side-effects of radiation therapy in cancer patients using ImmuneRegen's proprietary compound Radilex(TM). The parties believe that the solutions, based on completed and ongoing animal and cell culture studies, may also mitigate the effects of non-therapeutic radiation exposure. Radilex(TM) has already demonstrated through animal studies the potential for treatment of acute radiation syndrome (ARS) following lethal doses of radiation. Non-therapeutic radiation exposures might result following the explosion of a radiological dispersion device ("dirty bomb") or nuclear weapon. "It is our mission to participate in the identification and accelerated development of treatment modalities for cancer patients," said Stephen Gately, Director, Non-clinical Development at TD2. "We are enthusiastic and pleased to be working with ImmuneRegen on these promising applications for bio-defense and toxic therapy radiation exposure." "Based upon the promising results we have seen with Radilex to date in high-dose radiation exposure, we believe that the potential exists to apply the compound to the treatment of low-level radiation exposure, which represents a much larger market. We are excited to explore a number of potential applications in the area of oncology, this being the first," said Michael Wilhelm, ImmuneRegen CEO. Recently, ImmuneRegen announced that it had retained Battelle, the world's largest independent research and development organization, as an accredited testing facility. Battelle will perform additional specialized laboratory services supporting additional studies of the biological and radiological effectiveness of Radilex(TM). About TD2 About TGen About Radilex(TM) and Viprovex(TM) About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera® and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|